Contineum Therapeutics, Inc.

For the period ended Mar 31, 2025. Filed May 14, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 14, 2025

CTNM$10.56+2.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Statements of Cash Flows

(in thousands)

	Three Months Ended March 31,
	2025	2024
Operating activities
Net loss	$(15,990)	$(8,417)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization	78	61
Non-cash operating lease expense	233	244
Stock-based compensation	2,569	768
Accretion of premiums/discounts on marketable securities, net	(285)	(1,023)
Change in fair value of warrant liability	—	117
Gain on marketable securities	(2)	—
Loss on disposal of property and equipment	67	—
Changes in operating assets and liabilities
Prepaid expenses and other current assets	203	713
Accounts payable	1,834	(70)
Accrued expenses	(2,862)	(380)
Operating lease liabilities	(257)	12
Net cash used in operating activities	(14,412)	(7,975)
Investing activities
Purchase of property and equipment	(47)	(147)
Purchases of marketable securities	(33,691)	(30,640)
Sales and maturities of marketable securities	48,653	39,518
Net cash provided by investing activities	14,915	8,731
Financing activities
Payments of deferred offering costs	—	(140)
Proceeds from exercise of stock options	24	122
Net cash provided by (used in) financing activities	24	(18)
Net increase in cash and cash equivalents	527	738
Cash and cash equivalents at beginning of period	21,943	15,526
Cash and cash equivalents at end of period	$22,470	$16,264

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.